Symtuza
Payments companies reported to CMS as associated with Symtuza. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Symtuza, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Symtuza
These are the largest totals companies reported as associated with Symtuza. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joseph Gathe | Houston, TX | Infectious Disease | $107,567.97 |
| Elizabeth Race | Dallas, TX | Infectious Disease | $72,528.13 |
| Douglas Cunningham | Phoenix, AZ | Family Medicine | $67,194.89 |
| William Hardy | Los Angeles, CA | Internal Medicine | $45,475.91 |
| Gary Sinclair | Dallas, TX | Internal Medicine | $34,516.71 |
| Jihad Slim | Newark, NJ | Infectious Disease | $23,514.22 |
| Antonio Urbina | New York, NY | Infectious Disease | $22,589.57 |
| Brian Beesley | Columbus, OH | Family Medicine | $19,388.14 |
| Harish Moorjani | Briarcliff Manor, NY | Infectious Disease | $18,848.13 |
| Sheetal Sharma | Fort Lauderdale, FL | Internal Medicine | $18,342.83 |
Prescribed Symtuza?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.